title: Similar neurotoxicity of an alternating compared to a continuous low-dose schedule of thalidomide for relapsed/refractory multiple myeloma.
authors.forename: Silvia
authors.initials: S
authors.lastname: Mangiacavalli
authors.forename: Giovanni
authors.initials: G
authors.lastname: Albani
authors.forename: Tommaso
authors.initials: T
authors.lastname: Caravita
authors.forename: Federica
authors.initials: F
authors.lastname: Cocito
authors.forename: Cristiana
authors.initials: C
authors.lastname: Pascutto
authors.forename: Patrizia
authors.initials: P
authors.lastname: Zappasodi
authors.forename: Sara
authors.initials: S
authors.lastname: Bringhen
authors.forename: Antonio
authors.initials: A
authors.lastname: Palumbo
authors.forename: Mario
authors.initials: M
authors.lastname: Cazzola
authors.forename: Alessandro
authors.initials: A
authors.lastname: Corso
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000188:drug therapy*; D009422:Nervous System Diseases / Q000139:chemically induced*; D009460:Neurologic Examination; D011446:Prospective Studies; D012008:Recurrence; D016879:Salvage Therapy; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D007155:Immunologic Factors; D013792:Thalidomide